|
Vision Executives’ EYE-INTRO recruitment platform uses a science-based approach to recruitment to find the perfect candidate for your position. We not only interview and qualify candidates but test them via psychometric profiling and written competency assessments. 1️⃣ Firstly, we profile the position by asking our clients to complete a job survey which will provide an ideal personality type for the role according to how the client answers the questions about candidate ‘requirements’. 2️⃣ Following this, we then ask our candidates to complete a similar survey about their behaviour in their personal and professional lives. This allows us to compare the candidate’s personality with that required by the client, letting us see how strong a cultural fit the candidate will be for the position. 3️⃣ We then ask candidates to complete a few short-written questions to test their competency in various scenarios. ✅ Finally, via our EYE-INTRO platform you can score candidates according to how they have performed throughout the process giving you quantitative data to help you hire the right person. 🔥 This thorough search and selection process allowed us to achieve a 96% 1st year retention rate for the candidates we have placed and allows us to OFFER UP TO A 12 MONTH GUARENTEE ON CANDIDATES 🤯 If you are currently hiring for your team and want to find out more about our eyecare recruitment services, then please reach out to james.pickering@visionexecutives.com (Names & scores of candidates in the images are fictional)
0 Comments
ZEISS Medical Technology partnered with FCI Ophthalmic Community have announced their acquisition of two surgical instruments manufacturers: Kogent Surgical, LLC and Katalyst Surgical, LLC. "This is a strategically important acquisition for ZEISS Medical Technology. We expect this acquisition to scale the businesses and contribute to our surgical solution offering and add recurring revenue." Dr Markus Weber, CEO and President of Carl Zeiss Meditec AG. Kogent Surgical, LLC and Katalyst Surgical, LLC were founded by Gregg Scheller, who stated "We already have a successful, long-term partnership with ZEISS and FCI (France Chirurgie Instrumentation S.A.S.) and we look forward to jointly expanding our solutions into other ZEISS applications and customer specialties." Vision Executives look forward to seeing how this partnership and acquisition progresses. Follow Vision Executives to stay up to date with the latesteyecare news and vacancies.  We are pleased to welcome our new Candidate Relationship Manager Natasha Ellison to the Vision Executives team 👏👀 Having previously worked as an ophthalmic technician and in the recruitment industry Natasha is responsible for creating a seamless candidate experience for our extensive network of talented eyecare professionals. If you are looking for a new position in eyecare or ophthalmology please reach out to Natasha for a confidential call to discuss how we can support your career! Natasha.Ellison@visionexecutives.com Novartis have announced their European Commision Approval of Beovu, their treatment for Diabetic Macular Edema (DME). DME is a leading cause of vision loss in working-age people. In 2020, Beovu was granted European Commission Approval for the treatment of wet-age macular degeneration, making this newest announcement its second indication. The European Commission granted their approval following year 1 data from the phase 3 KESTREL and KITE studies which met their primary endpoint of noninferiority in change in best corrected visual acuity from baseline vs aflibercept. “This approval marks a significant milestone for DME patients, many of whom are of working age and struggle with adherence due to the need to manage multiple comorbidities related to diabetes” J. Jill Hopkins, MD, SVP and Global Development Unit Head of Ophthalmology for Novartis Pharmaceuticals. Previously, Novartis came into difficulties with Beovu. They halted three trials over safety concerns due to high rates of inflammatory reactions in the #eyes. With the advent of the news around DME, it would seem these safety issues have been resolved, with Novartis stating that the majority of the adverse events from Beovu for DME’s KESTREL and KITE studies ‘were manageable and resolved with routine clinical care’. Novartis’ application for Beovu for DME is also under review by the FDA and Japanese Pharmaceuticals and Medical Devices Agency. Follow Vision Executives to stay up to date with the latest eyecare news and vacancies.  Ref: https://eyewire.news/news/novartis-announces-european-commission-approval-of-beovu-for-diabetic-macular-edema-dme?c4src=article:infinite-scroll
|
AuthorJames Pickering is our Managing Director and an eye care recruitment expert who has developed an extensive client base and candidate network. He regularly writes articles about industry developments and has received numerous recommendations from industry leaders. You can also connect with James on LinkedIn to stay up to date on the latest eye care news. Archives
December 2022
Categories |
RSS Feed
|
Location |
|
Vision Executives Ltd is a company registered in England & Wales. Company Number 13319387.
Copyright © 2021 Vision Executives Ltd.
Click here to see our privacy policy.
Copyright © 2021 Vision Executives Ltd.
Click here to see our privacy policy.